Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Avastin off-licence

- PMLiVE

Irish survey lists pharma firms’ top five Brexit concerns

Talent access restrictions topped the list

- PMLiVE

NHS could save £7bn with greater diagnostics use

Report suggests IVD tests could be key to big savings

- PMLiVE

May earmarks £20bn for the NHS – but experts say it’s not enough

But claims of a “Brexit dividend” are rubbished

- PMLiVE

British Business Bank sets up £2.5bn fund for ‘unicorn’ firms

UK government says the private sector will bring in another £5bn in investments

- PMLiVE

Rosalind Franklin Institute invests £6m in disruptive technologies

Will open new AI-enabled research facility based in the UK

- PMLiVE

NICE backs Tesaro’s Zejula via the CDF

Recommends the drug for second-line use in ovarian cancer patients

Bayer symbol

Loxo, Bayer get quick FDA review for ‘precision’ cancer drug

Bayer and Loxo hopeful about novel biomarker-led cancer treatment

- PMLiVE

Digital skills gap hinders UK healthcare innovation

Report calls for greater emphasis on HCPs’ digital and data literacy education

- PMLiVE

NHS England pledges to streamline clinical trial setup

The process will also target the procedure for reimbursements in additional treatment costs

- PMLiVE

Daily Brief: Deal done, Takeda to cut $1.4bn, Brexit latest, Valeant rebrands

A rapid round-up of the top pharma, biotech and healthcare news

- PMLiVE

Regeneron’s Dupixent and Praluent falls short

But CEO Len Schleifer says there’s time to fix that

- PMLiVE

NHS England’s Simon Stevens – no Trump drug price rhetoric here

Health service supremo will play major role in UK pricing talks

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links